ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1309

Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid

Ji-Won Kim1, Ju-Yang Jung1, Hyoun-Ah Kim1 and Chang-Hee Suh2, 1Ajou University School of Medicine, Suwon, Republic of Korea, 2Ajou University Hospital, Suwon, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, glucocorticoids, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic acid is a convenient treatment option that allows compliance to be advantageous over other bisphosphonates. In this study, we aim to evaluate preference and patient satisfaction as well as the efficacy of zoledronic acid compared to other bisphosphonates.

Methods: Fifty patients with continued osteoporosis or new fractures were recruited in follow-up bone densitometry after taking oral bisphosphonates for at least 1 year in patients diagnosed with GIOP during treatment for autoimmune diseases. After 1 year of treatment with zoledronic acid, patients completed the survey to rate their preference and satisfaction. The treatment efficacy was analyzed by comparing the changes in bone density and fractures with patients maintaining oral bisphosphonates as controls.

Results: The mean age of patients was 64.1 years, 96% were female, and the mean duration of GIOP was 5.5 years. There was no difference in the cumulative glucocorticoid doses in zoledronic acid group and oral bisphosphonate group. Thirty-nine patients (78%) preferred and were more satisfied with intravenous zoledronic acid over oral bisphosphonates, and satisfaction was greatly affected by the administration interval and convenient regimen. The infusion-related adverse events of zoledronic acid were only 2 patients (4%). In terms of efficacy, there were no significant differences in annualized percentage change in bone density in the lumbar spine (1.9 ± 3.91 g/cm2 vs. 1 ± 5.3 g/cm2, p = 0.355), femur neck (-0.91 ± 6.31 g/cm2 vs. 0.41 ± 5.07 g/cm2, p = 0.264), and hip (0.29 ± 2.91 g/cm2 vs. 0.41 ± 5.07 g/cm2, p = 0.888) between patients who received zoledronic acid and those who took oral bisphosphonates. The occurrence of new fractures was two in each of the two groups, showing no difference.

Conclusion: In our study, zoledronic acid was preferred and more satisfactory by patients, and the treatment efficacy for osteoporosis was similar to oral bisphosphonates. Therefore, zoledronic acid is recommended as an appropriate treatment for GIOP in patients with autoimmune disease.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Kim, None; J. Jung, None; H. Kim, None; C. Suh, None.

To cite this abstract in AMA style:

Kim J, Jung J, Kim H, Suh C. Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-preference-and-efficacy-in-the-treatment-of-glucocorticoid-induced-osteoporosis-in-patients-with-autoimmune-diseases-receiving-zoledronic-acid/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-preference-and-efficacy-in-the-treatment-of-glucocorticoid-induced-osteoporosis-in-patients-with-autoimmune-diseases-receiving-zoledronic-acid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology